Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment

Volume 1 - Issue 5

Tomas Koltai*

Received: May 25, 2018;   Published: June 05, 2018

DOI: 10.32474/OAJOM.2018.01.000123

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphatidic acid (LPA), present in ascitic fluid, motivates the enlargement of malignant ovarian tumors by raising the appearance of vascular endothelial growth factor (VEGF) in ovarian cancer cells. Ovarian cancer cell progress is repressed by alendronate, a nitrogen containing biophosphate which attenuate the establishment of Rho by blocking the mevalonate pathway.

Abstract| Short Communication| References|